Twelve rectal cancer patients were entirely healed of the disease after taking a medicine for six months, which was a surprise result for an ongoing medical trial. Physical exams, endoscopies, bioscopies, PET scans, and MRI scans were all performed on the patients, and none of the reports revealed any signs of the tumour. The results were reported in the New England Journal of Medicine in a study. There are 32 authors listed in the publication. The study's original goal was to see if TSR-042 (commonly known as dostarlimab), in combination with routine chemoradiotherapy and surgery, was an effective treatment for advanced deficient MisMatch Repair (dMMR) solid tumours. The Simon and Eve Colin Foundation, GlaxoSmithKline, Stand Up to Cancer, Swim Across America, and the National Cancer Institute of the National Institutes of Health all contributed to the medical trial.

Key Points

• Twelve rectal cancer patients were entirely healed of the disease after taking a medicine for six months, which was a surprise result for an ongoing medical trial.

• The Simon and Eve Colin Foundation, GlaxoSmithKline, Stand Up to Cancer, Swim Across America, and the National Cancer Institute of the National Institutes of Health all contributed to the medical trial.

Follow Us On Google Newsstand: Click Here